OB-001
Asset
Overcomes ADC resistance and penetrates the blood-brain barrier to target tumors
- Stage
- Preclinical
- Modality
- Small molecule
- Target
- Not known
- 2
- Indications
- 0
- Trials
- 1
- Developer
Indications
2Cancer
Preclinical, prnewswire.com, 7 Oct 2026
Oncology
Preclinical, prnewswire.com, 7 Oct 2026
In the full profile
- Owner and partners1
- Competitors12
Every asset’s record: target, stage, trials and the evidence behind it.